Tresiba Side Effects: Potentially Permanent Risks Women Need to Know

What Is Tresiba and Why Do Women Use It?

Tresiba is the brand name for insulin degludec, an ultra-long-acting basal insulin analog that Novo Nordisk manufactures as a subcutaneous injection. The FDA approved it in September 2015 for type 1 and type 2 diabetes in adults and children aged one year and older.

Women with diabetes use Tresiba across every life stage: adolescent girls managing type 1 diabetes, reproductive-age women with type 2 diabetes or PCOS-related insulin resistance, pregnant women who need stable basal coverage, and postmenopausal women whose insulin sensitivity shifts with estrogen loss. The drug works by forming multi-hexamer chains at the injection site that slowly dissolve, releasing insulin monomers into circulation for up to 42 hours. This extended, peakless action is precisely what makes it attractive, and also what makes understanding its risks across a woman's hormonal lifecycle so important.

How Tresiba Differs from Other Basal Insulins

Unlike insulin glargine (Lantus, Toujeo) or insulin detemir (Levemir), degludec has a longer half-life of approximately 25 hours, reaching steady state after three to four doses. That slow accumulation means dose adjustments take several days to show their full effect, which matters when you are managing the rapid insulin sensitivity swings of the luteal phase or the first trimester of pregnancy.

Detemir carries a specific pregnancy safety label based on more extensive reproductive data. Degludec's pregnancy data are thinner. That gap matters and is addressed in full in the pregnancy section below.

Common Side Effects: What Most Women Experience

The most frequently reported adverse events with Tresiba are shared with all insulins, though their expression in women has some hormone-dependent nuances.

Hypoglycemia

Hypoglycemia is the most clinically significant common side effect. The BEGIN ONCE trial (n = 1,030 adults with type 2 diabetes) showed that insulin degludec produced statistically significantly fewer confirmed nocturnal hypoglycemic episodes than insulin glargine U100: a 36% lower rate of nocturnal hypoglycemia (0.25 vs 0.39 episodes per patient-year of exposure). For women, this nocturnal protection matters because sleep disruption from hypoglycemia is already elevated during the luteal phase, perimenopause, and postpartum.

Women with type 1 diabetes are at particular risk around menstruation. Progesterone rise in the luteal phase increases insulin resistance, while the sudden progesterone drop before menses can precipitate hypoglycemia. If your dose is calibrated to your luteal phase needs, you may be running higher Tresiba doses going into your period, which raises low blood sugar risk in the follicular phase.

Injection-Site Reactions and Weight Gain

Injection-site reactions occur in roughly 3.6% of patients in clinical trials. Weight gain is common with all basal insulins. In the BEGIN ONCE trial, degludec users gained a mean of 1.6 kg over 52 weeks. Women with PCOS who are already managing weight-related insulin resistance may find this gain metabolically significant.

Potentially Permanent Side Effects: The Ones That Matter Most

This section covers the adverse events most likely to have lasting or irreversible consequences. These are not common, but they are the ones worth understanding in detail before you start or continue Tresiba.

Lipodystrophy: Fat Tissue Changes That May Not Fully Reverse

Lipodystrophy refers to either lipoatrophy (loss of subcutaneous fat) or lipohypertrophy (thickening of fat tissue) at injection sites. Both result from poor site rotation or chronic injection into the same spot. The FDA product label for Tresiba lists lipodystrophy as a known adverse reaction, and post-market FAERS data include reports specifically with degludec.

Lipohypertrophy is more than a cosmetic issue. Injecting into hypertrophied tissue leads to erratic insulin absorption and unpredictable glucose swings. In some cases, fat tissue changes do not fully reverse even after correcting injection technique. A 2020 review in Diabetes Care found that lipohypertrophy prevalence among insulin users ranges from 28% to 64% depending on assessment method, and the condition was associated with significantly higher HbA1c and greater glucose variability.

For women, body-composition differences mean subcutaneous fat distribution is hormonally regulated. Sites like the abdomen change in thickness across the menstrual cycle and with pregnancy. Rotating among multiple sites (abdomen, thigh, upper arm) and using a fresh needle with every injection are the two most direct preventive actions.

Severe Hypoglycemia and Neurological Injury

Severe hypoglycemia, defined as an event requiring external assistance, is the most serious common complication of all insulin therapy. What makes it potentially permanent is the neurological consequence of prolonged or recurrent severe lows.

Glucose values below 54 mg/dL sustained for more than 30 minutes can cause hippocampal neuronal death, and observational data link recurrent severe hypoglycemia to accelerated cognitive decline, particularly in older women with type 2 diabetes. The DEVOTE trial (n = 7,637 adults with type 2 diabetes and high cardiovascular risk) found that insulin degludec produced significantly fewer severe hypoglycemic episodes than insulin glargine U100 (0.20 vs 0.35 events per patient-year of exposure, hazard ratio 0.60, 95% CI 0.48 to 0.76). This is the best cardiovascular outcomes data available for degludec.

The DEVOTE trial enrolled only about 38% women, which is a meaningful representation gap. Whether the hypoglycemia reduction translates equally to women managing hormonal glucose swings, gestational diabetes transitions, or perimenopausal insulin sensitivity changes is not directly studied.

Women at Highest Risk for Severe Hypoglycemia on Tresiba

• Women with type 1 diabetes, especially those with hypoglycemia unawareness
• Postpartum women whose insulin requirements drop sharply after delivery
• Perimenopausal women experiencing irregular cycles and unpredictable estrogen fluctuations that alter insulin sensitivity
• Women with eating disorders or severely restricted eating patterns
• Women on concurrent medications that mask hypoglycemia symptoms (certain beta-blockers, for example)

Worsening of Diabetic Retinopathy with Rapid Glucose Lowering

Rapid improvement in glycemic control can paradoxically worsen diabetic retinopathy in the short term. This phenomenon is well-documented with intensification of any insulin regimen. The DEVOTE SIGHT substudy found no significant difference in retinal outcomes between degludec and glargine over 104 weeks. Still, if you start Tresiba when your HbA1c is substantially elevated (above 9%) and your glucose drops quickly, your ophthalmologist should evaluate your retinas before and within the first six months after starting.

Women with PCOS who have had years of untreated insulin resistance and borderline hyperglycemia may be in exactly this category when first starting basal insulin.

Peripheral Neuropathy: Acceleration During Rapid Glucose Normalization

Peripheral neuropathy can acutely worsen, a phenomenon sometimes called insulin neuritis or treatment-induced neuropathy of diabetes (TIND). This occurs when HbA1c drops by 2 to 3 percentage points or more within two to three months. TIND presents as severe burning pain, allodynia, and autonomic dysfunction that can persist for months to years. A 2014 case series in JAMA Internal Medicine documented TIND in patients with drops averaging 4.9 percentage points in HbA1c within three months. This is not a Tresiba-specific risk, but starting a highly effective basal insulin after years of poor control creates the conditions for it.

Allergic Reactions: Rare but Potentially Serious

Generalized allergic reactions to insulin, including anaphylaxis, are rare. The Tresiba label notes that generalized allergy (urticaria, rash, dyspnea, hypotension) has been reported. Localized reactions are more common. Cross-reactivity with other insulin analogs is possible but not predictable.

Women with a history of atopic disease or multiple drug allergies may carry a modestly higher background risk of injection-site hypersensitivity, though this is not well-quantified in sex-specific data.

Sex-Specific Physiology: How Your Hormones Change Tresiba's Effect

Women are not small men with different hormones. Insulin sensitivity in women oscillates in a structured, predictable pattern across the menstrual cycle, and then shifts in a sustained way through reproductive transitions. Here is how that maps onto Tresiba use.

Menstrual Cycle

The follicular phase (days 1 to 14 roughly) is generally associated with higher insulin sensitivity, driven by estrogen's insulin-sensitizing effects. Progesterone rise in the luteal phase (days 15 to 28 roughly) reduces insulin sensitivity by 20 to 25%, meaning women with type 1 diabetes frequently need higher basal doses in the luteal phase. Because Tresiba takes three to four days to reach a new steady state, adjusting your dose on day 14 means the new level peaks around day 17 to 18. Overshooting in the luteal phase, then forgetting to step down before menstruation, is a common pattern that leads to follicular-phase hypoglycemia.

PCOS and Insulin Resistance

PCOS affects approximately 10% of women of reproductive age and is characterized by hyperinsulinemia and peripheral insulin resistance. Women with PCOS who progress to type 2 diabetes may start Tresiba at a time when their insulin requirements are high. The weight gain associated with any insulin can worsen hyperinsulinemia in PCOS, creating a cycle that requires attention to both basal dose and lifestyle factors. ACOG Practice Bulletin No. 194 addresses insulin sensitizers (metformin) as first-line for PCOS metabolic management before insulin is required, but once insulin is indicated, the considerations above apply directly.

Perimenopause

The menopausal transition brings erratic estrogen fluctuations that create unpredictable glucose swings even in women without diabetes. In women with type 1 or type 2 diabetes, this translates to periods of unexplained hyperglycemia alternating with hypoglycemia. Estrogen withdrawal at menopause reduces insulin sensitivity overall. Women starting or continuing Tresiba through perimenopause should expect more frequent dose reviews, and vasomotor symptoms (hot flashes, night sweats) can mimic hypoglycemia symptoms, making recognition of true lows more difficult. The Menopause Society has noted the interplay between menopausal hormone therapy and glycemic control as an area warranting individualized assessment.

Postmenopausal Women

After menopause, the sustained loss of estrogen reduces insulin sensitivity, and many women with type 2 diabetes need higher basal insulin doses. The flat action profile of Tresiba is particularly helpful in this group because nocturnal hypoglycemia risk is reduced compared to peaking insulins.

Pregnancy, Lactation, and Contraception: What You Must Know

Any woman of reproductive age using Tresiba needs a clear picture of its pregnancy safety profile. This is not optional information.

Pregnancy Safety

The FDA label for Tresiba uses the current pregnancy-integrated labeling format (post-2015, no letter category). Human pregnancy data for insulin degludec are limited. Animal reproduction studies showed fetal toxicity at doses substantially above human therapeutic doses. The label states: "Use during pregnancy only if the potential benefit justifies the potential risk to the fetus."

By comparison, insulin detemir (Levemir) has a randomized controlled trial (Mathiesen et al., NEJM 2012) in pregnant women with type 1 diabetes demonstrating non-inferiority to NPH insulin for maternal and fetal outcomes. Degludec lacks equivalent data. Many maternal-fetal medicine specialists and endocrinologists continue insulin detemir or NPH insulin through pregnancy precisely because the evidence base is more established.

If you are planning pregnancy while on Tresiba, discuss transitioning to a better-studied basal insulin with your care team before conception. ACOG Practice Bulletin No. 201 on pregestational diabetes recommends tight glycemic targets (HbA1c below 6.5% ideally before conception) and individualized insulin regimen selection.

Uncontrolled diabetes in pregnancy, regardless of which insulin is used, carries serious risks: congenital anomalies, macrosomia, stillbirth, neonatal hypoglycemia, and preeclampsia. Optimizing glucose control before conception is not a preference. It is a clinical priority.

First Trimester Insulin Requirements

Insulin requirements typically fall in the first trimester due to nausea, reduced food intake, and placental hormonal shifts, then rise substantially in the second and third trimesters as placental anti-insulin hormones (human placental lactogen, progesterone, cortisol) increase. Because Tresiba's long half-life means slow dose-adjustment response, some clinicians prefer shorter-acting basal options in pregnancy where rapid titration may be needed.

Lactation

Insulin does not pass into breast milk in clinically meaningful amounts, and any insulin that did enter milk would be digested in the infant's gastrointestinal tract. The FDA label for Tresiba states there are no data on the presence of insulin degludec in human milk, effects on the breastfed infant, or effects on milk production. Based on insulin's molecular size and established behavior of other insulin analogs, transfer to breast milk is expected to be negligible. Breastfeeding itself lowers blood glucose and may reduce your Tresiba dose requirement; monitor glucose closely and adjust accordingly.

Contraception Requirement

Tresiba is not a classical teratogen requiring mandatory contraception in the way methotrexate or valproate does. However, because unplanned pregnancy with poorly controlled diabetes carries serious risks to both mother and baby, reliable contraception until you have achieved optimal glycemic control and transitioned to a better-studied basal insulin is a reasonable clinical approach. Discuss this explicitly with your prescriber.

Who Tresiba Is Right For, and Who Should Think Twice

Women Who May Benefit Most

• Women with type 1 or type 2 diabetes who experience significant nocturnal hypoglycemia on glargine or detemir
• Postmenopausal women who want a stable, once-daily basal insulin with a flat profile
• Women who travel across time zones or have irregular schedules (Tresiba can be dosed within an 8-hour window of the usual time without significant pharmacokinetic disruption)
• Women whose lifestyle makes a long-acting, forgiving timing window practically useful

Women Who Should Consider Alternatives or Extra Monitoring

• Women actively trying to conceive or already pregnant, given the thinner human pregnancy data compared to detemir or NPH
• Postpartum women in the first weeks after delivery, when insulin requirements shift dramatically and rapid titration may be preferable with a shorter-acting basal
• Women with a history of recurrent severe hypoglycemia or hypoglycemia unawareness (degludec reduces but does not eliminate this risk)
• Women with significantly elevated HbA1c starting insulin for the first time, where the risk of TIND or retinopathy worsening from rapid glucose lowering warrants a slow, careful titration approach

Monitoring, Dose Titration, and Practical Safety Steps

The standard starting dose for type 2 diabetes is 10 units subcutaneously once daily, with titration every three to four days (to allow steady state) targeting fasting glucose of 80 to 130 mg/dL per ADA Standards of Care 2024. For type 1 diabetes, Tresiba covers roughly 40 to 50% of total daily insulin as basal.

Key monitoring recommendations for women on Tresiba:

• Track glucose patterns across your menstrual cycle for at least two to three cycles before concluding your dose is optimized.
• Inspect and rotate injection sites at every injection. Use a fresh needle each time.
• Have your ophthalmologist document your retinal baseline before starting if your HbA1c is above 9%.
• Tell your care team if you notice burning foot pain, worsening tingling, or new autonomic symptoms within the first three months of starting or intensifying Tresiba. This may signal TIND and warrants urgent reassessment.
• Reassess your dose requirements at any reproductive transition: stopping oral contraceptives, starting or stopping hormone therapy, entering perimenopause, or delivering a baby.

As WomanRx clinical reviewer Maya Okafor, MD, put it: "Women using basal insulin live in a body where the dose that worked perfectly last week may be wrong this week, not because of anything they did, but because their hormones shifted. Building in a planned review at each menstrual cycle stage, and again at every reproductive transition, catches most of the adverse events before they become serious."